SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending as investors discuss its potential in the AI infrastructure market, drawing comparisons to NVDA and DELL, with community members highlighting its growth potential and key role in data centers. Talk centers on the stock's ability to fill the gap, potential short squeeze, and anticipation for upcoming earnings and contract news. Some traders are expressing frustration over the stock's volatile price action and perceived lack of management credibility.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending as investors discuss the company's potential, particularly highlighting progress on commissioning new data centers and the anticipation of a hyperscaler deal announcement. The community is buzzing with bullish sentiment, envisioning significant revenue growth and comparing APLD to other successful stocks in the AI and data center space. Some traders are discussing potential upcoming earnings and the possibility of a short squeeze.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

RDDT is trending downwards, with community members citing a sharp drop and higher than average volume as potential concerns. Some are attributing the volatility to hedge fund manipulation and debate whether recent price action presents a buying opportunity or a sign of further decline. The community is also closely watching for any news or partnerships that could influence the stock's trajectory.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as a "culture coin" with a community focused on growth, freedom, and innovation. The coin is gaining attention for its unique approach, aiming to blend cannabis culture with cryptocurrency. Community members highlight its potential for long-term success, steady progress, and the ability to create a new direction in the crypto space.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing pressure as prediction markets gain traction, with concerns about their potential impact on traditional sports betting revenue driving community discussion. Investors are analyzing the competitive landscape, regulatory implications, and DraftKings' strategic response, including potential entry into prediction markets. The stock's recent price decline has sparked debates about its valuation and management's ability to navigate the evolving industry dynamics.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors focus on the potential for deep-sea mining and its role in securing critical minerals. Bullish sentiment is fueled by discussions of potential government funding and the possibility of breaking through the $7 resistance level, with many calling for a continued push upwards. The community is closely watching for news catalysts and anticipating a significant move soon.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid a call for subscription cancellations, spurred by controversy over content and executive actions. Community discussion revolves around differing viewpoints on content choices and their potential impact. The stock's movement is being closely watched, with some traders anticipating a possible squeeze while others eye potential downside.

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI is trending due to a mix of bullish earnings news and a short seller report, sparking debate among investors. The community is discussing the company's growth potential, contrasting it with the short seller's claims. High trading volume and the tug-of-war between bulls and bears contribute to the stock's current volatility and heightened interest.

Angel Studios, Inc. is a values-based distribution company for stories that amplify light to mainstream audiences. The company is headquartered in Provo, UT.

Angel Studios Inc. - Ordinary Shares - Class A

Angel Studios Inc

Angel Studios Inc is trending as the community anticipates news and eyes a potential after-hours surge, with some suggesting a target price. Chatter revolves around the possibility of big movements, potentially fueled by news related to a well-known figure in the tech world. Some see it as a potential giant in the entertainment space, drawing comparisons to Netflix.

Fermi Inc

Fermi LLC

Fermi (FRMI) is trending after its recent IPO, with the stock experiencing significant volatility and a notable after-hours surge. The community is focused on its potential in AI-powered data centers and nuclear energy, drawing both excitement and skepticism about its long-term prospects as a pre-revenue company. Some are optimistic about quick gains, while others plan to hold long-term, awaiting further developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics

CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.

Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Aldeyra Therapeutics (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Are Medical Stocks Lagging  Amgen (AMGN) This Year?

Here is how Amgen (AMGN) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.

Shares of Aldeyra Therapeutics, Inc. (ALDX) slumped nearly 71% on Thursday morning after it <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-receives-complete-response-letter-us-food-0">said</a> that the U.S. Food and Drug Administration (FDA) said the company’s investigational drug candidate reproxalap failed to demonstrate efficacy in treating ocular symptoms associated with dry eyes.The FDA told the company to resubmit its application for reproxalap and called upon the company to conduct “at least one additional adequate and well-controlled study” to demonstrate the drug’s positive effect on treating ocular symptoms of dry eye.The FDA, however, identified no manufacturing or safety issues with reproxalap, the company said.Aldeyra first submitted an application to the FDA for reproxalap in November 2022, but the agency asked for more trials. The company subsequently resubmitted its application in October 2024.Aldeyra Therapeutics CEO Todd C Brady said the company looks forward to a potential application resubmission by mid-year 2025, pending positive results from ongoing clinical trials and discussions with the FDA.On Stocktwits, retail investor sentiment about Aldeyra jumped further into the ‘extremely bullish’ territory (96/100), while message volume remained ‘extremely high’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:649/156;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_03_at_10_14_30_AM_png_cb23178c6c.webp" alt="ALDX's Sentiment Meter and Message Volume as of 10:10 a.m. ET on April 3, 2025 | Source: Stocktwits" width="649" height="156"><figcaption>ALDX's Sentiment Meter and Message Volume as of 10:10 a.m. ET on April 3, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the dip is a good opportunity to buy, highlighting the company’s cash balance. Aldeyra reported cash, cash equivalents, and marketable securities of $101 million as of the end of 2024.<stembedurl>https://stocktwits.com/Pizza_guy/message/610251728</stembedurl>Another user, however, speculated the company may be facing bankruptcy.<stembedurl>https://stocktwits.com/jacobs0009/message/610251451</stembedurl><a href="https://stocktwits.com/symbol/ALDX">Aldeyra shares</a> are down by over 70% this year and by over 60% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/poni-ai-gets-robotaxi-testing-permit-in-luxembourg/chf7R7QRbe0">Pony AI Stock Draws Investor Attention On Robotaxi Testing Permit In Luxembourg: Retail Stays Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays Optimistic

Aldeyra Therapeutics CEO Todd C Brady said the company looks forward to a potential application resubmission by mid-year 2025, pending positive results from ongoing clinical trials and discussions with the FDA.

Equity

Aldeyra Therapeutics CEO Todd C Brady said the company looks forward to a potential application resubmission by mid-year 2025, pending positive results from ongoing clinical trials and discussions with the FDA.


Aldeyra Therapeutics to Participate in Oppenheimers 35th Annual Healthcare Life Sciences Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today...

Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical...

Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

&nbsp;The stock market rally stalled on Tuesday, with the S&amp;P 500 Index retreating from its record closing high of 6,001.35. The weakness could be due to traders taking profit off their recent gains and shifting to the sidelines ahead of some key Main Street data on inflation and retail sales.IT, real-estate and industrial stocks served as drags, while the strength in the consumer discretionary and financial spaces offset some of the weakness.As the market pauses, here’s a compilation of stocks retailers on the Stocktwits platform are most bullish and bearish about:Most BullishNeuronetics, Inc. ($STIM)Pennsylvania-based Neuronetics, a commercial-stage med-tech company has seen its shares plunge hard following its third-quarter earnings announcement. The loss per share of $0.44 grossly missed the consensus loss estimate of $0.23, and revenue of $18.53 million also trailed the $19.14 million.The stock plunged about 40% but retail is ‘extremely” bullish on the stock.Zscaler, Inc. ($ZS)Shares of Zscaler, a San Jose, California-based cybersecurity company, rose nearly 3% on&nbsp;Tuesday following an announcement regarding its “Zero Trust Segmentation” solution.&nbsp;This solution will “provide a more secure, agile and cost-effective means to connect users, devices, and workloads across and within globally distributed branches, factories, campuses, data centers, and public clouds,” the company said.Axsome Therapeutics, Inc. ($AXSM)New York-based Axsome, which focuses on central nervous system disorders, reported a double beat for the third quarter. The stock rose over 6% following the quarterly results. The company has an FDA decision date in late January for its migraine treatment candidate.&nbsp;“We expect a busy end to the year with several clinical catalysts anticipated, including a planned simultaneous release of topline results from the ongoing Phase 3 ADVANCE-2 and ACCORD-2 trials of AXS-05 in Alzheimer’s disease agitation in the fourth quarter,” said CEO Herriot Tabuteau.Bitcoin Depot, Inc. ($BTM)Atlanta, Georgia-based Bitcoin Depot provides users with simple and efficient ways to convert cash into Bitcoin ($BTC.X).&nbsp;The company’s shares are pulling back after Monday’s 54% jump but retail held on to its bullish bias.MediciNova, Inc. ($MNOV)La Jolla, California-based MediciNova, said it was notified by Sanofi ($SNY) that the Sanofi/Novartis AG ($NVS) litigation was settled. This provides for MediciNova receiving&nbsp;a certain amount of monetary damages through this settlement. MediciNova’s stock jumped following the news, triggering positive reaction from the retail crowd.Most BearishReviva Pharmaceuticals, Holdings, Inc. ($RVPH)Reviva, a late-stage&nbsp;pharma developing therapies in the areas of central nervous system, inflammatory and cardiometabolic diseases, announced a positive update on the enrollment for the ongoing 1-year open-label extension study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia. The stock climbed about 33% on Tuesday but retail sentiment was at a rock bottom.Pagaya Technologies Ltd. ($PGY)Israel-based Pagaya, a provider of&nbsp;financial products and services, reported a loss for the third quarter, which was much wider than expected. The stock slumped over 35%. Some among the retailers called outt the company a “fraud.Aldeyra Therapeutics, Inc. ($ALDX)Lexington, Massachusetts-based Aldeyra is a biotech focusing on therapies for immune-mediated and metabolic diseases. The shares of the company plunged on Tuesday on just about average volume.&nbsp;Retailers on the Stocktwits platform fretted over poor data for its dry eye disease product candidate.&nbsp;Quantum-Si Inc. ($QSI)Protein sequencing company Quantum-Si’s shares plunged over 22% on Tuesday after the&nbsp; Branford, Connecticut-based company reported its third-quarter results.ViaSat, Inc. ($VSAT)Shares of Carlsbad, California-based ViaSat have been ailing ever since the satellite telecommunications reported its financial results for the fiscal year 2025 second-quarter results last Thursday. This, in turn, has dented retail sentiment.&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/euphoric-run-of-tesla-stock-catalyzed-by-election-result-stalled/cJ40dh1ROF">Tesla Stock’s Post-Election Rally Stalls But Analyst Talks Up His $500 Bull-Case Scenario: Retail Mood Stays Sou</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

A slew of biopharma stocks made big moves on Tuesday. 

10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday

Earnings largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$5.24
Prev Close	$5.22
Open	$5.17
Dividend Yield	0.00%
50-Day Moving Average	$5.36
Beta	2.47
Avg. Volume	858,542.24
PE Ratio	-6.16

52-Week High	$7.20
52-Week Low	$1.14
Market Capitalization	$312.65M
EPS (Annual)	-$0.9389
Price to Book	5.67
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ALDX
Aldeyra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALDX News

ALDX Aldeyra Therapeutics Inc